TY - JOUR

T1 - Outcome of COVID-19 in allogeneic stem cell transplant recipients

T2 - Results from the EPICOVIDEHA registry

AU - Busca, Alessandro

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - Farina, Francesca

AU - Seval, Guldane Cengiz

AU - Van Doesum, Jaap

AU - De Jonge, Nick

AU - Bahr, Nathan C.

AU - Maertens, Johan

AU - Meletiadis, Joseph

AU - Fracchiolla, Nicola S.

AU - Weinbergerová, Barbora

AU - Verga, Luisa

AU - Ráčil, Zdeněk

AU - Jiménez, Moraima

AU - Glenthøj, Andreas

AU - Blennow, Ola

AU - Tanase, Alina Daniela

AU - Schönlein, Martin

AU - Prezioso, Lucia

AU - Khanna, Nina

AU - Duarte, Rafael F.

AU - Žák, Pavel

AU - Nucci, Marcio

AU - Machado, Marina

AU - Kulasekararaj, Austin

AU - Espigado, Ildefonso

AU - De Kort, Elizabeth

AU - Ribera-Santa Susana, José María

AU - Marchetti, Monia

AU - Magliano, Gabriele

AU - Falces-Romero, Iker

AU - Ilhan, Osman

AU - Ammatuna, Emanuele

AU - Zompi, Sofia

AU - Tsirigotis, Panagiotis

AU - Antoniadou, Anastasia

AU - Zambrotta, Giovanni Paolo Maria

AU - Nordlander, Anna

AU - Karlsson, Linda Katharina

AU - Hanakova, Michaela

AU - Dragonetti, Giulia

AU - Cabirta, Alba

AU - Berg Venemyr, Caroline

AU - Gräfe, Stefanie

AU - Van Praet, Jens

AU - Tragiannidis, Athanasios

AU - Petzer, Verena

AU - López-García, Alberto

AU - Itri, Federico

AU - Groh, Ana

AU - Gavriilaki, Eleni

AU - Dargenio, Michelina

AU - Rahimli, Laman

AU - Cornely, Oliver A.

AU - Pagano, Livio

N1 - Publisher Copyright: Copyright © 2023 Busca, Salmanton-García, Marchesi, Farina, Seval, Van Doesum, De Jonge, Bahr, Maertens, Meletiadis, Fracchiolla, Weinbergerová, Verga, Ráčil, Jiménez, Glenthøj, Blennow, Tanase, Schönlein, Prezioso, Khanna, Duarte, Žák, Nucci, Machado, Kulasekararaj, Espigado, De Kort, Ribera-Santa Susana, Marchetti, Magliano, Falces-Romero, Ilhan, Ammatuna, Zompi, Tsirigotis, Antoniadou, Zambrotta, Nordlander, Karlsson, Hanakova, Dragonetti, Cabirta, Berg Venemyr, Gräfe, Van Praet, Tragiannidis, Petzer, López-García, Itri, Groh, Gavriilaki, Dargenio, Rahimli, Cornely, Pagano and EPICOVIDEHA Consortium.

PY - 2023

Y1 - 2023

N2 - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

AB - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

KW - allogeneic HSCT

KW - COVID-19 infection

KW - hematological malignances

KW - immunocompromised patients

KW - SARS-CoV-2

U2 - 10.3389/fimmu.2023.1125030

DO - 10.3389/fimmu.2023.1125030

M3 - Journal article

C2 - 36911708

AN - SCOPUS:85149866062

VL - 14

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1125030

ER -